Experiences of gamma hydroxybutyrate (GHB) ingestion: a focus group study.
GHB (gamma hydroxybutyrate) is a significant new drug of abuse added to the United States Controlled Substance Act in 2000. The majority of the published literature on GHB consists of clinical case reports, mainly from emergency departments, and a collection of laboratory-based studies, focused mainly on anesthesia. While comments about the various experiences and behaviors of human users are often included in such studies or reports, these aspects of GHB are only just beginning to be systematically investigated or detailed. Reported here are data from a qualitative study using focus group methods on the consumption habits, experiences, and beliefs of GHB users. A total of 51 people, 30 men and 21 women, mean age of 31.1+/-7.6 years (range 18 to 52 years), who report having used GHB for an average of 4.3+/-2.5 years (range one to 11 years), were interviewed in 10 separate groups held in 2004. This article discusses broadly the general experience of the GHB high, major perceived benefits including sexual responses to the drug, perceived risks and dangers of ingestion, co-ingestion, and various contexts of use. It concludes with a discussion of the implications drawn from this information for clinicians treating patients who use GHB.
Barker
Judith C
JC
Department of Anthropology, History & Social Medicine, University of California, San Francisco 94143-0850, USA. barkerj@dahsm.ucsf.edu
Harris
Shana L
SL
Dyer
Jo E
JE
D000293:Adolescent; D000328:Adult; D005260:Female; D017144:Focus Groups; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D013287:Illicit Drugs / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D018570:Risk Assessment; D012725:Sexual Behavior / Q000187:drug effects; D012978:Sodium Oxybate / Q000008:administration & dosage / Q000009:adverse effects*; D019966:Substance-Related Disorders / Q000453:epidemiology* / Q000523:psychology*
D013287:Illicit Drugs; D012978:Sodium Oxybate
Am J Psychiatry. 2005 Aug;162(8):1494-502
16055770
J Clin Psychopharmacol. 2006 Oct;26(5):524-9
16974199
Am J Addict. 2001 Summer;10(3):232-41
11579621
Am J Public Health. 2001 Jun;91(6):953-8
11392940
Schweiz Med Wochenschr. 2000 Mar 11;130(10):356-61
10763213
Int J Drug Policy. 2006 Jan 1;17(1):23-28
23543728
Clin Pharmacol Ther. 2007 Feb;81(2):178-84
17192771
Addict Behav. 2006 Jan;31(1):137-42
15907371
Am Fam Physician. 2004 Jun 1;69(11):2619-26
15202696
Ann Emerg Med. 2003 Jul;42(1):3-8
12827115
Ann Emerg Med. 2006 Feb;47(2):177-83
16431231
J Subst Abuse. 2001;13(1-2):119-26
11547613
J Psychoactive Drugs. 2004 Sep;36(3):401-2
15559687
N Engl J Med. 2005 Jun 30;352(26):2721-32
15987921
Ann Emerg Med. 1998 Jun;31(6):716-22
9624311
Drug Alcohol Depend. 2002 Jun 1;67(1):89-94
12062782
Am J Addict. 2004 Mar-Apr;13(2):120-7
15204663
Am J Emerg Med. 2005 May;23(3):316-20
15915404
J Med Toxicol. 2007 Mar;3(1):7-14
18072152
Subst Use Misuse. 2008;43(11):1507-20
18752156
Subst Use Misuse. 2005;40(9-10):1203-40
16048814
Drug Alcohol Depend. 2001 Sep 1;64(1):9-17
11470336
Addiction. 2003 Feb;98(2):199-204
12534425
Addiction. 2003 Dec;98(12):1693-703
14651501
CMAJ. 2000 Jun 27;162(13):1843-8
10906922
N Engl J Med. 2001 Jan 11;344(2):87-94
11150358